Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.48 |
| ▸ | FABP1 | P07148 | 3/20 | 0.46 |
| ▸ | FABP4 | P15090 | 1/20 | 0.44 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22790320 | 0.91 | NR1H4 (0.43) | NR1H4FABP1 | |
| SCHEMBL22790209 | 0.88 | NR1H4 (0.45) | NR1H4FABP1 | |
| SCHEMBL20952439 | 0.86 | NR1H4 (0.46) | NR1H4FABP1FABP4HSD17B13 | |
| SCHEMBL28417927 | 0.86 | NR1H4 (0.46) | NR1H4FABP1FABP4HSD17B13 | |
| SCHEMBL21326421 | 0.86 | NR1H4 (0.48) | NR1H4 | |
| SCHEMBL24638811 | 0.83 | NR1H4 (0.39) | NR1H4 | |
| SCHEMBL28895205 | 0.80 | NR1H4 (0.51) | NR1H4FABP1 | |
| SCHEMBL22789969 | 0.80 | NR1H4 (0.47) | NR1H4FABP1 | |
| SCHEMBL22789944 | 0.80 | NR1H4 (0.53) | NR1H4FABP1FABP4HSD17B13 | |
| SCHEMBL21693720 | 0.78 | NR1H4 (0.46) | NR1H4FABP1FABP4HSD17B13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111278821-B | Spiro compounds as farnesol X receptor modulators | 百时美施贵宝公司 | 2023-10-03 | — | — | CN | disclosed |
| US-20230295141-A1 | FXR SMALL MOLECULE AGONIST, THE PREPARATION AND USE THEREOF | CASCADE PHARMACEUTICALS, INC. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230295141-A1 | FXR SMALL MOLECULE AGONIST, THE PREPARATION AND USE THEREOF | CASCADE PHARMACEUTICALS, INC. (CN) | 2023-09-21 | — | — | US | disclosed |
| EP-4245365-A1 | A FXR SMALL MOLECULE AGONIST, THE PREPARATION AND USE THEREOF | Cascade Pharmaceuticals, Inc. (CN) | 2023-09-20 | — | — | EP | disclosed |
| EP-3535260-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AS FXR MODULATORS | HEPAGENE THERAPEUTICS HK LTD (HK) | 2023-08-30 | — | — | EP | disclosed |
| EP-3535260-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AS FXR MODULATORS | HEPAGENE THERAPEUTICS HK LTD (HK) | 2023-08-30 | — | — | EP | disclosed |
| CN-114315844-B | FXR regulator and preparation method and application thereof | 中国科学院上海药物研究所 | 2023-06-27 | — | — | CN | disclosed |
| CN-111511731-B | Olefin compounds as modulators of the farnesol X receptor | 百时美施贵宝公司 | 2023-05-23 | — | — | CN | disclosed |
| EP-3704106-B1 | ALKENE COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-12 | — | — | EP | disclosed |
| CN-109963849-B | Nitrogen-containing heterocyclic compounds as FXR modulators | 和博医药有限公司 | 2023-03-28 | — | — | CN | disclosed |
| EP-3535260-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AS FXR MODULATORS | Hepagene Therapeutics, Inc. (VG) | 2019-09-11 | — | — | EP | disclosed |
| US-20190248752-A1 | HETEROCYCLIC FXR MODULATORS | Hepagene Therapeutics (HK) Limited (HK) | 2019-08-15 | — | — | US | disclosed |
| US-20190194216-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2019118571-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2019-06-20 | — | — | WO | disclosed |
| US-20190127362-A1 | SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-02 | — | — | US | disclosed |
| US-20190127362-A1 | SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-02 | — | — | US | disclosed |
| WO-2018075207-A1 | HETEROCYCLIC FXR MODULATORS | HEPAGENE THERAPEUTICS, INC. (VG) | 2018-04-26 | — | — | WO | disclosed |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-04-12 | — | — | US | disclosed |
| WO-2018067704-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127362-A1 | SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | NR1H4, FXR1, NR1H2 | NR1H4 1/4885FABP1 56/4885FABP4 487/4885 |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | GPBAR1, SLC10A1, NR1H4 | NR1H4 3/4885FABP1 17/4885FABP4 394/4885 |
| US-20190248752-A1 | HETEROCYCLIC FXR MODULATORS | NR1H4, FXR1, NR1H2 | NR1H4 1/4885FABP1 12/4885FABP4 107/4885 |
| US-20190194216-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | SLC10A1, NR1H4, GPBAR1 | NR1H4 2/4885FABP1 42/4885FABP4 515/4885 |
| US-20230295141-A1 | FXR SMALL MOLECULE AGONIST, THE PREPARATION AND USE THEREOF | FXR1, NR1H4, FXR2 | NR1H4 2/4885FABP1 47/4885FABP4 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.